去年8月,其靶向CD3与GPRC5D的双特异性T细胞结合抗体Talvey(talquetamab)获美国FDA用于治疗复发性或难治性多发性骨髓瘤成人患者。强生在2023年5月与Cellular Biomedicine Group(CBMG),获得CBMG的双特异性自体CAR-T疗法,并在今年初通过斥资20亿美元Ambrx Biopharma扩充其抗体偶联药物(ADC)管线。这个月初,强生的在研抗体...
Despite recent layoffs and closures in the state, there are still many companies actively recruiting for roles in California.
去年8月,其靶向CD3与GPRC5D的双特异性T细胞结合抗体Talvey(talquetamab)获美国FDA加速批准用于治疗复发性或难治性多发性骨髓瘤成人患者。强生在2023年5月与Cellular Biomedicine Group(CBMG)达成合作,获得CBMG的双特异性自体CAR-T疗法,并在今年初通过斥资20...
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year. The life sciences industry has been thriving this year, and young companies are reaping the benefits by pulling in millions of dollars in financing r...
[1] Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData. Retrieved February 21, 2024 from网页链接 [2] Lilly Edges Out J&J to Top 20 BioPharma Market Cap List for 2023. Retrieved February 21, 2024 from网页链接 ...
Top 10 global pharmaceutical companies by revenue 2023 Enterprise value of top pharmaceutical companies globally 2022 Worldwide biopharma M&A transaction volume by location 2015-2019 Satisfaction or desire for received pharmaceutical services in the U.S. 2013 ...
Bristol Myers Squibb is a biopharma company with a focus on research in immunology. The company’s pipeline of testing for new drugs covers more than 40 different disease areas. To further its strategic goals, Bristol Myers Squibb has partnered with several big-name pharmaceutical companies like ...
Started in: 2008 Founders: Austin Che, Barry Canton, Jason Kelly, Reshma Shetty, Tom Knight Industries: Biopharma, Biotechnology, Chemical Number of employees: 501-1000 Funding: $798,728,100 Funding rounds: 9 Number of investors: 33 (General Atlantic, Felicis Ventures, Bill Gates, MassChallenge...
Shanghai, China: April 16th, 2021, The Fifth Future Healthcare VB100 Conference enlisted Zhimeng Biopharma as one of the Top 100 Biotech Companies in China. The listing recognizes the company's "strong potential in growth in both R&D and capital field." ...
1.https://www.biospace.com/article/eli-lilly-edges-out-j-and-j-to-top-20-biopharma-market-cap-list-for-2023-/ 2.https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-report-1-6-market-capitalization-growth-to-3-67-trillion-in-2023-reveals-globaldata...